
News|Articles|August 1, 2009
FDA Pipeline preview, August 2009 (trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, velaglucerase alfa)
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
5
































